GRI
GRI Bio, Inc. Common Stock
stockNASDAQ
gri is a development stage biotech company fundamentally changing the way inflammatory disease is treated. gri's natural killer t (nkt) cell-based therapies are being developed for liver disease and acute liver failure. nkt cells share properties of both nk and t cells and are a functional link between the innate and adaptive immune responses. type 1 nkt cells play a critical role in initiating and propagating the inflammatory response and the hepatic injury that is observed in liver disease. gri's lead program, gri-0621, is an inhibitor of type i nkt cells and is being developed as a novel oral therapeutic for acute liver failure.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.10 | 2026-09-28 | -7.14% | 4.716 |
| 1M | 2.88 | 2026-09-04 | -32.29% | 1.874 |
| 3M | 1.81 | 2026-07-06 | +7.74% | 1.151 |
| 6M | 2.41 | 2026-04-06 | -19.09% | 0.586 |
| 1Y | 56.00 | 2025-10-06 | -96.52% | 0.880 |
| 2Y | 170.41 | 2024-10-04 | -98.86% | — |
| 5Y | 371,867.86 | 2023-04-24 | -100.00% | 0.993 |
GRI Bio, Inc. Common Stock (NASDAQ:GRI) stock price today is $1.95, and today's volume is 41,482. GRI is down 0.510% today. The 30 day average volume is 417,306. GRI market cap is $4.26M with 2.19M shares outstanding.